Eintrag weiter verarbeiten
Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey
Gespeichert in:
| Zeitschriftentitel: | Clinical Cardiology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , |
| In: | Clinical Cardiology, 33, 2010, 3, S. 172-178 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Kowey, Peter R. Breithardt, Günter Camm, John Crijns, Harry Dorian, Paul Le Heuzey, Jean‐Yves Pedrazzini, Laurence Prystowsky, Eric N. Salette, Geneviève Schwartz, Peter J. Torp‐Pedersen, Christian Weintraub, William Kowey, Peter R. Breithardt, Günter Camm, John Crijns, Harry Dorian, Paul Le Heuzey, Jean‐Yves Pedrazzini, Laurence Prystowsky, Eric N. Salette, Geneviève Schwartz, Peter J. Torp‐Pedersen, Christian Weintraub, William |
|---|---|
| author |
Kowey, Peter R. Breithardt, Günter Camm, John Crijns, Harry Dorian, Paul Le Heuzey, Jean‐Yves Pedrazzini, Laurence Prystowsky, Eric N. Salette, Geneviève Schwartz, Peter J. Torp‐Pedersen, Christian Weintraub, William |
| spellingShingle |
Kowey, Peter R. Breithardt, Günter Camm, John Crijns, Harry Dorian, Paul Le Heuzey, Jean‐Yves Pedrazzini, Laurence Prystowsky, Eric N. Salette, Geneviève Schwartz, Peter J. Torp‐Pedersen, Christian Weintraub, William Clinical Cardiology Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey Cardiology and Cardiovascular Medicine General Medicine |
| author_sort |
kowey, peter r. |
| spelling |
Kowey, Peter R. Breithardt, Günter Camm, John Crijns, Harry Dorian, Paul Le Heuzey, Jean‐Yves Pedrazzini, Laurence Prystowsky, Eric N. Salette, Geneviève Schwartz, Peter J. Torp‐Pedersen, Christian Weintraub, William 0160-9289 1932-8737 Wiley Cardiology and Cardiovascular Medicine General Medicine http://dx.doi.org/10.1002/clc.20737 <jats:title>Abstract</jats:title><jats:sec><jats:title>Background:</jats:title><jats:p>The Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation (RecordAF) study is the first worldwide, prospective, survey of real‐life management of atrial fibrillation (AF) in recently diagnosed patients (n = 5604) with a 1‐year follow‐up.</jats:p></jats:sec><jats:sec><jats:title>Hypothesis:</jats:title><jats:p>Surveys of AF management have identified a divergence between guidelines and clinical practice, and an overinterpretation of guidelines in low‐risk patients.</jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p>Physicians' theoretical approaches to rhythm and rate control were investigated using a pre‐study questionnaire.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>One cardiologist, from each of the 583 sites in 6 regions, completed a questionnaire on their practice and management of AF patients. In AF patients with structural heart disease (SHD), amiodarone was the most frequent choice of first‐line rhythm control agents in all regions. Amiodarone or sotalol tended to be the preferred second‐line rhythm control agents, 1 exception being Central/South America. β‐Blockers were the first‐line rate control agents for patients with AF and SHD in all regions, and calcium channel blockers and cardiac glycosides were the most common second‐line rate control treatments in all regions, except Asia. In lone AF patients, propafenone (30.6%), flecainide (24.1%), and amiodarone (21.7%) were the most common global choices of first‐line rhythm control, and amiodarone or sotalol were the preferred second‐line rhythm control agents, 1 exception being Central/South America.</jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p>These results highlight points of divergence from the American College of Cardiology (ACC)/ American Heart Association (AHA)/European Society of Cardiology (ESC) guidelines for the management of AF in terms of first‐line drug selection in patients with associated SHD or coronary artery disease. Copyright © 2010 Wiley Periodicals, Inc.</jats:p></jats:sec> Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey Clinical Cardiology |
| doi_str_mv |
10.1002/clc.20737 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9jbGMuMjA3Mzc |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9jbGMuMjA3Mzc |
| institution |
DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 |
| imprint |
Wiley, 2010 |
| imprint_str_mv |
Wiley, 2010 |
| issn |
0160-9289 1932-8737 |
| issn_str_mv |
0160-9289 1932-8737 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
kowey2010physicianstatedatrialfibrillationmanagementinlightoftreatmentguidelinesdatafromaninternationalobservationalprospectivesurvey |
| publishDateSort |
2010 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Clinical Cardiology |
| source_id |
49 |
| title |
Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey |
| title_unstemmed |
Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey |
| title_full |
Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey |
| title_fullStr |
Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey |
| title_full_unstemmed |
Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey |
| title_short |
Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey |
| title_sort |
physician stated atrial fibrillation management in light of treatment guidelines: data from an international, observational prospective survey |
| topic |
Cardiology and Cardiovascular Medicine General Medicine |
| url |
http://dx.doi.org/10.1002/clc.20737 |
| publishDate |
2010 |
| physical |
172-178 |
| description |
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background:</jats:title><jats:p>The Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation (RecordAF) study is the first worldwide, prospective, survey of real‐life management of atrial fibrillation (AF) in recently diagnosed patients (n = 5604) with a 1‐year follow‐up.</jats:p></jats:sec><jats:sec><jats:title>Hypothesis:</jats:title><jats:p>Surveys of AF management have identified a divergence between guidelines and clinical practice, and an overinterpretation of guidelines in low‐risk patients.</jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p>Physicians' theoretical approaches to rhythm and rate control were investigated using a pre‐study questionnaire.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>One cardiologist, from each of the 583 sites in 6 regions, completed a questionnaire on their practice and management of AF patients. In AF patients with structural heart disease (SHD), amiodarone was the most frequent choice of first‐line rhythm control agents in all regions. Amiodarone or sotalol tended to be the preferred second‐line rhythm control agents, 1 exception being Central/South America. β‐Blockers were the first‐line rate control agents for patients with AF and SHD in all regions, and calcium channel blockers and cardiac glycosides were the most common second‐line rate control treatments in all regions, except Asia. In lone AF patients, propafenone (30.6%), flecainide (24.1%), and amiodarone (21.7%) were the most common global choices of first‐line rhythm control, and amiodarone or sotalol were the preferred second‐line rhythm control agents, 1 exception being Central/South America.</jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p>These results highlight points of divergence from the American College of Cardiology (ACC)/ American Heart Association (AHA)/European Society of Cardiology (ESC) guidelines for the management of AF in terms of first‐line drug selection in patients with associated SHD or coronary artery disease. Copyright © 2010 Wiley Periodicals, Inc.</jats:p></jats:sec> |
| container_issue |
3 |
| container_start_page |
172 |
| container_title |
Clinical Cardiology |
| container_volume |
33 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792339371626594305 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:46:27.594Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Physician+Stated+Atrial+Fibrillation+Management+in+Light+of+Treatment+Guidelines%3A+Data+From+an+International%2C+Observational+Prospective+Survey&rft.date=2010-03-01&genre=article&issn=1932-8737&volume=33&issue=3&spage=172&epage=178&pages=172-178&jtitle=Clinical+Cardiology&atitle=Physician+Stated+Atrial+Fibrillation+Management+in+Light+of+Treatment+Guidelines%3A+Data+From+an+International%2C+Observational+Prospective+Survey&aulast=Weintraub&aufirst=William&rft_id=info%3Adoi%2F10.1002%2Fclc.20737&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792339371626594305 |
| author | Kowey, Peter R., Breithardt, Günter, Camm, John, Crijns, Harry, Dorian, Paul, Le Heuzey, Jean‐Yves, Pedrazzini, Laurence, Prystowsky, Eric N., Salette, Geneviève, Schwartz, Peter J., Torp‐Pedersen, Christian, Weintraub, William |
| author_facet | Kowey, Peter R., Breithardt, Günter, Camm, John, Crijns, Harry, Dorian, Paul, Le Heuzey, Jean‐Yves, Pedrazzini, Laurence, Prystowsky, Eric N., Salette, Geneviève, Schwartz, Peter J., Torp‐Pedersen, Christian, Weintraub, William, Kowey, Peter R., Breithardt, Günter, Camm, John, Crijns, Harry, Dorian, Paul, Le Heuzey, Jean‐Yves, Pedrazzini, Laurence, Prystowsky, Eric N., Salette, Geneviève, Schwartz, Peter J., Torp‐Pedersen, Christian, Weintraub, William |
| author_sort | kowey, peter r. |
| container_issue | 3 |
| container_start_page | 172 |
| container_title | Clinical Cardiology |
| container_volume | 33 |
| description | <jats:title>Abstract</jats:title><jats:sec><jats:title>Background:</jats:title><jats:p>The Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation (RecordAF) study is the first worldwide, prospective, survey of real‐life management of atrial fibrillation (AF) in recently diagnosed patients (n = 5604) with a 1‐year follow‐up.</jats:p></jats:sec><jats:sec><jats:title>Hypothesis:</jats:title><jats:p>Surveys of AF management have identified a divergence between guidelines and clinical practice, and an overinterpretation of guidelines in low‐risk patients.</jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p>Physicians' theoretical approaches to rhythm and rate control were investigated using a pre‐study questionnaire.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>One cardiologist, from each of the 583 sites in 6 regions, completed a questionnaire on their practice and management of AF patients. In AF patients with structural heart disease (SHD), amiodarone was the most frequent choice of first‐line rhythm control agents in all regions. Amiodarone or sotalol tended to be the preferred second‐line rhythm control agents, 1 exception being Central/South America. β‐Blockers were the first‐line rate control agents for patients with AF and SHD in all regions, and calcium channel blockers and cardiac glycosides were the most common second‐line rate control treatments in all regions, except Asia. In lone AF patients, propafenone (30.6%), flecainide (24.1%), and amiodarone (21.7%) were the most common global choices of first‐line rhythm control, and amiodarone or sotalol were the preferred second‐line rhythm control agents, 1 exception being Central/South America.</jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p>These results highlight points of divergence from the American College of Cardiology (ACC)/ American Heart Association (AHA)/European Society of Cardiology (ESC) guidelines for the management of AF in terms of first‐line drug selection in patients with associated SHD or coronary artery disease. Copyright © 2010 Wiley Periodicals, Inc.</jats:p></jats:sec> |
| doi_str_mv | 10.1002/clc.20737 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9jbGMuMjA3Mzc |
| imprint | Wiley, 2010 |
| imprint_str_mv | Wiley, 2010 |
| institution | DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15 |
| issn | 0160-9289, 1932-8737 |
| issn_str_mv | 0160-9289, 1932-8737 |
| language | English |
| last_indexed | 2024-03-01T15:46:27.594Z |
| match_str | kowey2010physicianstatedatrialfibrillationmanagementinlightoftreatmentguidelinesdatafromaninternationalobservationalprospectivesurvey |
| mega_collection | Wiley (CrossRef) |
| physical | 172-178 |
| publishDate | 2010 |
| publishDateSort | 2010 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Clinical Cardiology |
| source_id | 49 |
| spelling | Kowey, Peter R. Breithardt, Günter Camm, John Crijns, Harry Dorian, Paul Le Heuzey, Jean‐Yves Pedrazzini, Laurence Prystowsky, Eric N. Salette, Geneviève Schwartz, Peter J. Torp‐Pedersen, Christian Weintraub, William 0160-9289 1932-8737 Wiley Cardiology and Cardiovascular Medicine General Medicine http://dx.doi.org/10.1002/clc.20737 <jats:title>Abstract</jats:title><jats:sec><jats:title>Background:</jats:title><jats:p>The Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation (RecordAF) study is the first worldwide, prospective, survey of real‐life management of atrial fibrillation (AF) in recently diagnosed patients (n = 5604) with a 1‐year follow‐up.</jats:p></jats:sec><jats:sec><jats:title>Hypothesis:</jats:title><jats:p>Surveys of AF management have identified a divergence between guidelines and clinical practice, and an overinterpretation of guidelines in low‐risk patients.</jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p>Physicians' theoretical approaches to rhythm and rate control were investigated using a pre‐study questionnaire.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>One cardiologist, from each of the 583 sites in 6 regions, completed a questionnaire on their practice and management of AF patients. In AF patients with structural heart disease (SHD), amiodarone was the most frequent choice of first‐line rhythm control agents in all regions. Amiodarone or sotalol tended to be the preferred second‐line rhythm control agents, 1 exception being Central/South America. β‐Blockers were the first‐line rate control agents for patients with AF and SHD in all regions, and calcium channel blockers and cardiac glycosides were the most common second‐line rate control treatments in all regions, except Asia. In lone AF patients, propafenone (30.6%), flecainide (24.1%), and amiodarone (21.7%) were the most common global choices of first‐line rhythm control, and amiodarone or sotalol were the preferred second‐line rhythm control agents, 1 exception being Central/South America.</jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p>These results highlight points of divergence from the American College of Cardiology (ACC)/ American Heart Association (AHA)/European Society of Cardiology (ESC) guidelines for the management of AF in terms of first‐line drug selection in patients with associated SHD or coronary artery disease. Copyright © 2010 Wiley Periodicals, Inc.</jats:p></jats:sec> Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey Clinical Cardiology |
| spellingShingle | Kowey, Peter R., Breithardt, Günter, Camm, John, Crijns, Harry, Dorian, Paul, Le Heuzey, Jean‐Yves, Pedrazzini, Laurence, Prystowsky, Eric N., Salette, Geneviève, Schwartz, Peter J., Torp‐Pedersen, Christian, Weintraub, William, Clinical Cardiology, Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey, Cardiology and Cardiovascular Medicine, General Medicine |
| title | Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey |
| title_full | Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey |
| title_fullStr | Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey |
| title_full_unstemmed | Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey |
| title_short | Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey |
| title_sort | physician stated atrial fibrillation management in light of treatment guidelines: data from an international, observational prospective survey |
| title_unstemmed | Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey |
| topic | Cardiology and Cardiovascular Medicine, General Medicine |
| url | http://dx.doi.org/10.1002/clc.20737 |